Key Developments: Life Technologies Corp (LIFEC.MU)
57.34EUR
24 May 2013
€0.06 (+0.10%)
€57.37
€57.34
€57.34
€57.34
--
562
€57.40
€32.07
Latest Key Developments (Source: Significant Developments)
Life Technologies Corp Issues Q2 2013 Guidance Below Analysts' Estimates-Conference Call
Life Technologies Corp announced that for the second quarter of 2013, it expects revenue in the range of $950 million to $955 million and non-GAAP diluted earnings per share (EPS) in the range of $0.94 to $0.97. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $980 million and EPS of $1.06 for the second quarter of 2013. Full Article
Frontier IP Group PLC's Portfolio Company Announces Healthcare Research Collaboration with Life Technologies Corp
Frontier IP Group PLC announced that one of its portfolio companies, Aridhia Informatics Limited ("Aridhia") is a lead commercial partner alongside Life Technologies Corp, a global biotechnology tools company, in the Stratified Medicine Scotland Innovation Centre (SMS-IC). Aridhia will provide the biomedical informatics platform and experience required to collect, manage and analyse the volume and diversity of data that is needed to realise the potential of stratified medicine, while Life Technologies Corp will deliver the DNA sequencing technology required to drive discovery and genetic analysis. Together, the two companies can support the development of detailed patient records integrating genomic and clinical data in order to explore the complex relationships between biological pathways and drug response. Full Article
Law Office Of Brodsky & Smith, LLC Announces Investigation Of Life Technologies Corp
Law Office Of Brodsky & Smith, LLC announced that it is investigating potential claims against the Board of Directors of Life Technologies Corp. (Life or the Company) relating to the reported acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher). Under the terms of the transaction Life Shareholders will receive $76 in cash for each share of Life stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Life for not acting in the Company’s shareholders' interests in connection with the sale process. The market for gene tests, like the one sold by Life, may grow to $25 billion within a decade as more doctors use a patient’s genetic makeup to tailor treatments. Full Article
Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By Board Of Life Technologies Corp
Levi & Korsinsky is investigating the Board of Directors of Life Technologies Corporation for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Thermo Fisher Scientific, Inc. Under the terms of the transaction, Life Technologies shareholders will receive $76 for each share of Life Technologies stock they own. The transaction has a total approximate value of $13.6 billion. The investigation concerns whether the Life Technologies Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether Thermo Fisher Scientific, Inc. is underpaying for Life Technologies stock, thus unlawfully harming Life Technologies stockholders. Full Article
Brodsky & Smith, LLC Announces Investigation of Life Technologies Corp
Law office of Brodsky & Smith, LLC announced that it is investigating potential claims against the Board of Directors of Life Technologies Corp (Life or the Company) relating to the reported acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher). Under the terms of the transaction Life Shareholders will receive $76 in cash for each share of Life stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Life for not acting in the Company's shareholders' best interests in connection with the sale process. The market for gene tests, like the one sold by Life, may grow to $25 billion within a decade as more doctors use a patient's genetic makeup to tailor treatments. Full Article
Former Attorney General of Louisiana and Kahn Swick & Foti, LLC Investigate Life Technologies Corp
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC announced that KSF has commenced an investigation into the Board of Directors of Life Technologies Corp (Life Technologies or the Company) in connection with their conduct related to the sale of the Company to Thermo Fisher Scientific. Under the terms of the proposed transaction, shareholders of Life Technologies will receive $76 in cash for each share of Life Technologies common stock that they own. KSF`s investigation is focusing on whether Life Technologies and/or its officers and directors secured sufficient value for the shareholders of Life Technologies and/or violated state or federal securities laws. Full Article
Ryan & Maniskas, LLP Announces Investigation of Life Technologies Corp
Ryan & Maniskas, LLP announced that it is investigating potential claims against the board of directors of Life Technologies Corp (Life Technologies or the Company) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Thermo Fisher Scientific in an all-cash deal valued at approximately $13.6 billion, including the assumption of the Company's net debt in the amount of $2.2 billion. Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by the Company's board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Life Technologies. Under the terms of the proposed transaction, Life Technologies' stockholders will receive $76 in cash for each share of Life Technologies common stock they own. Full Article
Faruqi & Faruqi, LLP Seeks More Cash For Shareholders Of Life Technologies Corp
Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, announced that it is investigating the Board of Directors of Life Technologies Corp for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Thermo Fisher Scientific in an all-cash deal valued at approximately $13.6 billion, including the assumption of the Company’s net debt in the amount of $2.2 billion. Under the terms of the proposed transaction, Life Technologies’ stockholders will receive $76 in cash for each share of Life Technologies common stock they own. The investigation focuses on whether Life Technologies’ Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Life Technologies’ shareholders. Full Article
Briscoe Law Firm and Powers Taylor, LLP Investigate Life Technologies Corp Sale to Thermo Fisher Scientific
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP announced that they are investigating the sale of Life Technologies Corp (Life) to Thermo Fisher Scientific, Inc. for shareholders. Under the terms of the proposed deal valued at approximately $13.6 billion, Life shareholders will only receive $76.00 in cash for each share of Life stock owned. The Life sale investigation centers on whether Life`s shareholders are receiving adequate compensation for their shares in the proposed deal, whether the transaction undervalues Life`s stock, and whether Life`s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Full Article
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Life Technologies Corp Shareholders
Kirby McInerney LLP announced that it is investigating potential claims against the Board of Directors of Life Technologies Corp (Life Technologies or the Company) related to the proposed acquisition of the Company by Thermo Fisher Scientific (Thermo Fisher). Under the terms of the agreement, Thermo Fisher will acquire all of the outstanding common stock of Life Technologies for $76.00 per fully diluted common share in cash, for a total transaction value of approximately $13.6 billion. The investigation concerns whether the Life Technologies Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $76.00 per share consideration adequately values Life Technologies common shares. Full Article
Roche, Sigma teamed up for failed Life Technologies bid: sources
NEW YORK - Roche Holding AG teamed up with Sigma-Aldrich Corp to make an unsuccessful bid for Life Technologies Corp earlier this year, people familiar with the matter said.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
